Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma

Journal of Human Genetics

Volumn 62, Issue 1, 2017, Pages 113-121

  Koshizuka, Keiichi ^a,b   Hanazawa, Toyoyuki ^b   Fukumoto, Ichiro ^a,b   Kikkawa, Naoko ^b   Matsushita, Ryosuke ^c   Mataki, Hiroko ^c   Mizuno, Keiko ^c   Okamoto, Yoshitaka ^b   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 1; MICRORNA 260; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MIRN1 MICRORNA, HUMAN; MIRN206 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; RNA SEQUENCE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 85008625156     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2016.47     Document Type: Article

References (46)

1. Leemans, C. R., Braakhuis, B. J. & Brakenhoff, R. H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22 (2011).
2. Carthew, R. W. & Sontheimer, E. J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655 (2009).
3. Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114 (2008).
4. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).
5. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
6. Wiemer, E. A. The role of microRNAs in cancer: no small matter. Eur. J. Cancer 43, 1529-1544 (2007).
7. Iorio, M. V. & Croce, C. M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848-5856 (2009).
8. Fukumoto, I., Hanazawa, T., Kinoshita, T., Kikkawa, N., Koshizuka, K., Goto, Y. et al. MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA-26a/b in the modulation of novel cancer pathways. Br. J. Cancer 112, 891-900 (2015).
9. Fukumoto, I., Kinoshita, T., Hanazawa, T., Kikkawa, N., Chiyomaru, T., Enokida, H. et al. Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. Br. J. Cancer 111, 386-394 (2014).
10. Kikkawa, N., Hanazawa, T., Fujimura, L., Nohata, N., Suzuki, H., Chazono, H. et al. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br. J. Cancer 103, 877-884 (2010).
11. Nohata, N., Hanazawa, T., Kikkawa, N., Sakurai, D., Fujimura, L., Chiyomaru, T. et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br. J. Cancer 105, 833-841 (2011).
12. Fukumoto, I., Kikkawa, N., Matsushita, R., Kato, M., Kurozumi, A., Nishikawa, R. et al. Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. J. Hum. Genet. 61, 109-118 (2016).
13. Kinoshita, T., Hanazawa, T., Nohata, N., Kikkawa, N., Enokida, H., Yoshino, H. et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 3, 1386-1400 (2012).
14. Kinoshita, T., Nohata, N., Hanazawa, T., Kikkawa, N., Yamamoto, N., Yoshino, H. et al. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br. J. Cancer 109, 2636-2645 (2013).
15. Gilcrease, M. Z. Integrin signaling in epithelial cells. Cancer Lett. 247, 1-25 (2007).
16. Kim, S. H., Turnbull, J. & Guimond, S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 209, 139-151 (2011).
17. Kurozumi, A., Goto, Y., Matsushita, R., Fukumoto, I., Kato, M., Nishikawa, R. et al. Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci. 107, 84-94 (2015).
18. Nohata, N., Hanazawa, T., Enokida, H. & Seki, N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3, 9-21 (2012).
19. Nohata, N., Hanazawa, T., Kikkawa, N., Mutallip, M., Sakurai, D., Fujimura, L. et al. Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J. Hum. Genet. 56, 595-601 (2011).
20. Nohata, N., Sone, Y., Hanazawa, T., Fuse, M., Kikkawa, N., Yoshino, H. et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2, 29-42 (2011).
21. Mataki, H., Seki, N., Chiyomaru, T., Enokida, H., Goto, Y., Kumamoto, T. et al. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Int. J. Oncol. 46, 1039-1050 (2015).
22. Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E., Rangell, L. et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin. Cancer Res. 20, 4488-4498 (2014).
23. Kalyankrishna, S. & Grandis, J. R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24, 2666-2672 (2006).
24. Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N. et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176 (2006).
25. Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V., Nallasura, V., El Dinali, M. et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-3031 (2009).
26. Datta, J., Kutay, H., Nasser, M. W., Nuovo, G. J., Wang, B., Majumder, S. et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68, 5049-5058 (2008).
27. Nasser, M. W., Datta, J., Nuovo, G., Kutay, H., Motiwala, T., Majumder, S. et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283, 33394-33405 (2008).
28. Song, G. & Wang, L. Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism. PLoS ONE 4, e6880 (2009).
29. Mataki, H., Enokida, H., Chiyomaru, T., Mizuno, K., Matsushita, R., Goto, Y. et al. Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. J. Hum. Genet. 60, 53-61 (2015).
30. Migliore, C., Martin, V., Leoni, V. P., Restivo, A., Atzori, L., Petrelli, A. et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin. Cancer Res. 18, 737-747 (2012).
31. Yan, D., Dong Xda, E., Chen, X., Wang, L., Lu, C., Wang, J. et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J. Biol. Chem. 284, 29596-29604 (2009).
32. Yoshino, H., Chiyomaru, T., Enokida, H., Kawakami, K., Tatarano, S., Nishiyama, K. et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br. J. Cancer 104, 808-818 (2011).
33. Lin, F., Yao, L., Xiao, J., Liu, D. & Ni, Z. MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther. 7, 1583-1591 (2014).
34. Zhang, L., Liu, X., Jin, H., Guo, X., Xia, L., Chen, Z. et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 332, 94-101 (2013).
35. Yang, Q., Zhang, C., Huang, B., Li, H., Zhang, R., Huang, Y. et al. Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. Eur. J. Gastroenterol. Hepatol. 25, 953-957 (2013).
36. Rajalingam, K., Schreck, R., Rapp, U. R. & Albert, S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177-1195 (2007).
37. Caulin, C., Nguyen, T., Longley, M. A., Zhou, Z., Wang, X. J. & Roop, D. R. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res. 64, 5054-5058 (2004).
38. Han, C., Zhou, Y., An, Q., Li, F., Li, D., Zhang, X. et al. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. Tumour Biol. 36, 6715-6723 (2015).
39. Liu, L., Shao, X., Gao, W., Zhang, Z., Liu, P., Wang, R. et al. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 279, 3800-3812 (2012).
40. Cui, W., Zhang, S., Shan, C., Zhou, L. & Zhou, Z. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J. 280, 3962-3974 (2013).
41. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
42. Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116-1127 (2008).
43. Bertotti, A. & Sassi, F. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies. Clin. Cancer Res. 21, 3377-3383 (2015).
44. Rabinowits, G. & Haddad, R. I. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 48, 1085-1089 (2012).
45. Madoz-Gurpide, J., Zazo, S., Chamizo, C., Casado, V., Carames, C., Gavin, E. et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J. Transl. Med. 13, 282 (2015).
46. Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S. et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47, 1025-1037 (2008).